Who does not qualify for a home sleep test, and why

A home sleep apnea test is the wrong tool for some people, even if they snore and even if their insurer would rather mail a box. The 2017 American Academy of Sleep Medicine diagnostic guideline names the exclusions in a strong recommendation: significant cardiorespiratory disease, neuromuscular weakness that may impair breathing muscles, hypoventilation, chronic opioid use, stroke, and severe insomnia. A negative home test in anyone still suspected of apnea is not reassurance. It is an indication for in-lab polysomnography.

Why does the guideline keep a list at all?

Home testing is built for a narrow job: confirm obstructive sleep apnea in an uncomplicated adult who already looks like moderate to severe disease. The device records breathing and oxygen, or a related surrogate, while you sleep in your own bed. It does not stage sleep the way an attended study does. It is a poor window on central apnea, hypoventilation, and the other disorders that live in the same waiting room as snoring.

Kapur and colleagues therefore split the world in two. Uncomplicated patients at increased risk of moderate to severe OSA may be diagnosed with either polysomnography or a technically adequate home test. Everyone on the exclusion list should go to the lab instead. That is recommendation 4, and it is strong. It is not a suggestion that the home box is “less convenient.” It is a statement that the box can miss the physiology you actually have.

The rest of this article is that list, with the reason each item is there. If you recognize yourself, the next step is not to argue with a durable-medical supplier. It is to say so at the visit so the order matches the guideline. Westerville Sleep Center’s overview of sleep testing is the menu. This page is the “do not use the home test” column.

What counts as significant cardiorespiratory disease?

The guideline’s own remarks define an “uncomplicated” patient as someone without conditions that raise the risk of non-obstructive sleep-disordered breathing: central sleep apnea, hypoventilation, sleep-related hypoxemia. Significant cardiopulmonary disease is the first example. Heart failure, unstable coronary disease, and substantial lung disease sit in that bucket because nocturnal breathing in those patients is not just a collapsible throat.

A home oximeter will show desaturations. It will not tell you whether they came from obstructive events, from a low baseline because of COPD, from Cheyne-Stokes respiration, or from ventilation-perfusion mismatch that has nothing to do with the pharynx. Treating every jagged overnight oxygen trace as “sleep apnea” is how people get a CPAP they cannot use and a missed heart-failure workup.

You do not need to grade your own echocardiogram in the parking lot. You do need to put heart failure, COPD, pulmonary hypertension, and recent cardiac events on the table before anyone hands you a home recorder. If the physician still wants a home test, they should be able to say why you are an exception to a strong recommendation, not why it is cheaper.

Why does neuromuscular weakness require the lab?

Diseases that weaken the diaphragm and accessory muscles (ALS, advanced muscular dystrophy, myasthenia in crisis, and similar conditions) produce a different night than garden-variety obstructive apnea. The problem may be effort that cannot generate a breath, not a throat that will not stay open. Hypoventilation and sleep-related hypoxemia are the risks the guideline is naming.

Home apnea tests are scored around airflow and oxygen, or around peripheral arterial tone. They are not a substitute for measuring sleep, effort, and, when indicated, carbon dioxide. A “normal” home test in someone with neuromuscular disease can mean the device never saw the hypoventilation. An “abnormal” test can still leave you without the titration and ventilatory support questions that belong in an attended lab.

If you have a neuromuscular diagnosis, or unexplained orthopnea and a weak cough, say it early. The exclusion is about respiratory muscle weakness due to neuromuscular disease, not about every aching back.

What is hypoventilation doing on this list?

Awake hypoventilation, or a high suspicion of sleep-related hypoventilation, is its own bullet in recommendation 4. Obesity hypoventilation syndrome is the example most people in a sleep clinic will meet. The daytime clue is an elevated carbon dioxide, not a loud snore. The nighttime problem is inadequate ventilation, which may sit on top of obstruction or instead of it.

A home test that reports an apnea-hypopnea index does not measure CO2. It cannot diagnose hypoventilation. Starting auto-CPAP on a home-test AHI in that setting can leave hypercapnia untreated. The lab exists so the recording can include the channels needed to see hypoventilation and so a titration, if it happens, can move toward the right mode rather than the default consumer machine.

Suspicion is enough. You do not need a blood gas in your pocket to be kept off a home box. Unexplained bicarb elevation, marked obesity with awake oxygen in the 80s, or known daytime hypercapnia should stop the “just mail the test” reflex.

Why do chronic opioids block a home test?

Opioids depress respiratory drive. They are a classic setup for central sleep apnea and ataxic breathing. The 2017 remarks list chronic opiate medication use next to stroke and cardiopulmonary disease as a condition that raises the risk of non-obstructive sleep-disordered breathing.

A home recorder that looks at nasal pressure and belts, or at arterial tone, can under-count or mis-label those events. Central apneas also change what treatment is reasonable. A device that assumes every pause is obstructive will not warn you that the problem is drive, not collapse.

Chronic use is the word in the guideline. A three-day prescription after a dental extraction is a different conversation from daily methadone, long-acting oxycodone, or other standing opioid therapy. Bring the bottle list. If the home test was already done on opioids and called “mild OSA,” treat that report as incomplete until a physician who knows the exclusion looks at it.

Why is a history of stroke an exclusion?

Stroke appears twice in the 2017 materials: in the definition of an uncomplicated patient, and in the strong recommendation to use polysomnography rather than home testing. Cerebrovascular disease is associated with both obstructive and central events. Sleep-related hypoventilation and disordered respiratory control are in the differential. A home test aimed at confirming garden-variety OSA is the wrong first instrument.

Timing matters clinically even when the guideline does not print a waiting period. A recent infarct, ongoing rehabilitation, and residual weakness that affects the airway or the chest wall all push toward an attended study, or toward waiting until the patient can be studied safely. Do not let a vendor recast “history of stroke” as “history of snoring after a stroke.”

If the only sleep complaint after a stroke is daytime sleepiness, the differential also includes the stroke itself, medications, and mood. That is another reason the lab, which can look at sleep architecture and movement, is the default.

Why does severe insomnia belong with heart failure and opioids?

Severe insomnia is listed because it interferes with the accuracy of a home test, not because insomnia is a form of apnea. Home devices estimate a respiratory event index over recording time. They do not know, the way EEG does, when you were actually asleep. Hours of lights-out wakefulness dilute the index. Brief sleep with dense obstruction can be missed or mis-sized. People with severe insomnia also have a high rate of failed recordings: the cannula comes off, the night is spent reading, the file is technically inadequate.

The same at-a-glance document groups severe insomnia with other significant non-respiratory sleep disorders that either need their own evaluation (narcolepsy and other central hypersomnias, parasomnias, sleep-related movement disorders) or wreck the home tracing. If the presenting problem is “I don’t sleep,” a home apnea box is a detour. If the presenting problem is both (“I don’t sleep and I stop breathing”), the lab can look at both in one night.

Mild, situational insomnia is not the same sentence. The guideline’s word is severe. A physician has to make that call. Self-diagnosing “I have insomnia so I can’t have a home test” is not the move. Telling the office you take two hours to fall asleep most nights, or that you are on a hypnotic, is.

What if the home test already came back negative?

Recommendation 3 is also strong: if a single home sleep apnea test is negative, inconclusive, or technically inadequate, perform polysomnography. Home testing is less sensitive than an attended study. A normal-looking home file does not rule out OSA. It rules out, at best, obvious moderate to severe disease on that particular night with that particular device, in a patient who was a candidate for the test in the first place.

Inconclusive and technically inadequate are not bureaucratic synonyms for “try a second home box.” The guideline’s next step is the lab. Repeating a home test because the first one failed is a payer habit, not the AASM sequence.

If you were never a candidate (any item above), a negative home test is even less informative. The exclusion existed to keep you out of that pathway. Getting a normal result from the wrong test is how sleep apnea stays untreated while everyone files the report under “reassuring.”

What about the home itself?

The 2017 remarks add environmental or personal factors that preclude adequate acquisition and interpretation of home data. There is no questionnaire for this. Shift work with no habitual sleep period, a household where the device will not stay on, cognitive impairment without a caregiver to help with sensors, and a living situation that is not safe for unattended recording all belong here.

Insurers sometimes treat “home first” as a rule of nature. It is a coverage preference. It is not a license to ignore recommendation 4. If a plan insists on a home test in someone on the exclusion list, that is a prior-authorization fight, not a clinical conversion. The insurance and costs page is the place for how billing usually works. The physician’s note still has to say why the lab is medically necessary.

Call (614) 898-9340 with the comorbidity list in front of you. The visit is where the exclusion is applied. This article exists so that list is not a surprise after a box has already been shipped.